1
|
Tapela NM, Mpunga T, Hedt-Gauthier B, Moore M, Mpanumusingo E, Xu MJ, Nzayisenga I, Hategekimana V, Umuhizi DG, Pace LE, Bigirimana JB, Wang J, Driscoll C, Uwizeye FR, Drobac PC, Ngoga G, Shyirambere C, Muhayimana C, Lehmann L, Shulman LN. Pursuing equity in cancer care: implementation, challenges and preliminary findings of a public cancer referral center in rural Rwanda. BMC Cancer 2016; 16:237. [PMID: 26992690 PMCID: PMC4797361 DOI: 10.1186/s12885-016-2256-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2015] [Accepted: 03/08/2016] [Indexed: 11/29/2022] Open
Abstract
Background Cancer services are inaccessible in many low-income countries, and few published examples describe oncology programs within the public sector. In 2011, the Rwanda Ministry of Health (RMOH) established Butaro Cancer Center of Excellence (BCCOE) to expand cancer services nationally. In hopes of informing cancer care delivery in similar settings, we describe program-level experience implementing BCCOE, patient characteristics, and challenges encountered. Methods Butaro Cancer Center of Excellence was founded on diverse partnerships that emphasize capacity building. Services available include pathology-based diagnosis, basic imaging, chemotherapy, surgery, referral for radiotherapy, palliative care and socioeconomic access supports. Retrospective review of electronic medical records (EMR) of patients enrolled between July 1, 2012 and June 30, 2014 was conducted, supplemented by manual review of paper charts and programmatic records. Results In the program’s first 2 years, 2326 patients presented for cancer-related care. Of these, 70.5 % were female, 4.3 % children, and 74.3 % on public health insurance. In the first year, 66.3 % (n = 1144) were diagnosed with cancer. Leading adult diagnoses were breast, cervical, and skin cancer. Among children, nephroblastoma, acute lymphoblastic leukemia, and Hodgkin lymphoma were predominant. As of June 30, 2013, 95 cancer patients had died. Challenges encountered include documentation gaps and staff shortages. Conclusion Butaro Cancer Center of Excellence demonstrates that complex cancer care can be delivered in the most resource-constrained settings, accessible to vulnerable patients. Key attributes that have made BCCOE possible are: meaningful North–south partnerships, innovative task- and infrastructure-shifting, RMOH leadership, and an equity-driven agenda. Going forward, we will apply our experiences and lessons learned to further strengthen BCCOE, and employ the developed EMR system as a valuable platform to assess long-term clinical outcomes and improve care.
Collapse
Affiliation(s)
- Neo M Tapela
- Botswana Ministry of Health, Gaborone, Botswana. .,Dana-Farber/Brigham & Women's Cancer Center, Boston, USA. .,Harvard Medical School, Boston, USA. .,Division of Global Health Equity, Brigham and Women's Hospital, Boston, USA.
| | | | - Bethany Hedt-Gauthier
- Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda.,Dana-Farber/Brigham & Women's Cancer Center, Boston, USA.,Harvard Medical School, Boston, USA
| | - Molly Moore
- University of Vermont College of Medicine, Burlington, USA
| | | | | | | | | | | | | | | | - JingJing Wang
- Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda
| | | | | | - Peter C Drobac
- Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda.,Dana-Farber/Brigham & Women's Cancer Center, Boston, USA.,Harvard Medical School, Boston, USA
| | - Gedeon Ngoga
- Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda
| | | | | | - Leslie Lehmann
- Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda.,Dana-Farber/Brigham & Women's Cancer Center, Boston, USA.,Harvard Medical School, Boston, USA.,Boston Children's Hospital, Boston, USA
| | - Lawrence N Shulman
- Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda.,Dana-Farber/Brigham & Women's Cancer Center, Boston, USA.,Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| |
Collapse
|
2
|
Shyirambere C, Xu MJ, Elmore SN, Fadelu T, May L, Tapela N, Umuhizi DG, Uwizeye FR, Driscoll C, Muhayimana C, Hategekimana V, Rubagumya F, Nzayisenga I, Shulman LN, Mpunga T, Lehmann LE. Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model. J Glob Oncol 2016; 2:105-113. [PMID: 28717689 PMCID: PMC5495448 DOI: 10.1200/jgo.2015.000067] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internists and pediatricians, and data collection structured for monitoring and evaluation. Here, we report clinical outcomes and protocol compliance for patients with nephroblastoma evaluated at Butaro Cancer Center of Excellence in Rwanda. Patients and Methods This retrospective study reports the care of 53 patients evaluated between July 1, 2012, and June 30, 2014. Patients receiving less than half of their chemotherapy at Butaro Cancer Center of Excellence were excluded. Results Of the 53 patients included, 9.4% had stage I, 13.2% had stage II, 24.5% had stage III, 26.4% had stage IV, and 5.7% had stage V disease; the remaining 20.8% had unknown stage disease from inadequate work-up or unavailable surgical report. The incidence of neutropenia increased with treatment progression, and the greatest proportion of delays occurred during the surgical referral phase. At the end of the study period, 32.1% of patients (n = 17) remained alive after treatment; 24.5% (n = 13) remained alive while continuing treatment, including one patient with recurrent disease; 30.2% (n = 16) died; and 13.2% (n = 7) were lost to follow-up. Conclusion Our findings confirm that nephroblastoma can be effectively treated in resource-constrained settings. Using an approach in which chemotherapy is delivered at a rural-based center by nononcologists and data are used for routine evaluation, care can be delivered in safe, novel ways. Protocol modifications to mitigate chemotherapy toxicities and strong communication between the multidisciplinary team members will likely minimize delays and further improve outcomes in similar settings.
Collapse
Affiliation(s)
- Cyprien Shyirambere
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Mary Jue Xu
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Shekinah Nefreteri Elmore
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Temidayo Fadelu
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Leana May
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Neo Tapela
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Denis Gilbert Umuhizi
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Frank Regis Uwizeye
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Caitlin Driscoll
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Clemence Muhayimana
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Vedaste Hategekimana
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Fidel Rubagumya
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Ignace Nzayisenga
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Lawrence N Shulman
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Tharcisse Mpunga
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| | - Leslie E Lehmann
- , , , and , Inshuti Mu Buzima/Partners in Health Rwanda; , , , , and , Ministry of Health Rwanda, Kigali, Rwanda; , , , , and , Harvard Medical School; , , and , Brigham and Women's Hospital; and , Boston Children's Hospital; and , Dana-Farber Cancer Institute, Boston, MA; and , Icahn School of Medicine at Mount Sinai, New York, NY
| |
Collapse
|